NEMLUVIO (nemolizumab‑ilto) prior authorization for prurigo nodularis
Customize your policy alerts
Sign up for all Mississippi Division of Medicaid policy alerts
Know when Mississippi Division of Medicaid releases new policies or updates existing guidance.
Monitor payer policy activity
States prior authorization requirements for NEMLUVIO (nemolizumab‑ilto) for treatment of prurigo nodularis (PN) under Mississippi Division of Medicaid; applies to providers requesting PA for this drug.
No material clinical or coverage changes in this revision.
Coverage Criteria for NEMLUVIO (nemolizumab‑ilto)
Initial Authorization
Covered when ALL of the following are met
- Patient meets the minimum age and weight requirements recommended by the package insert for this FDA approved indication.
- Diagnosis of prurigo nodularis for a duration of at least 3 months.
- Prescribed by, or in consultation with, a dermatologist, allergist/immunologist, or other specialist in the treatment of prurigo nodularis.
- Severe or very severe itch with WINRS score ≥7 reported within the past month.
- At least 20 prurigo nodularis lesions total on both legs and/or both arms and/or trunk.
- Inadequate response after at least a 2-month trial of DUPIXENT (dupilumab).
- Prescribed dose does not exceed FDA-approved dosing based on patient age, weight, and diagnosis.
Re-Authorization
Covered upon re-authorization when ALL of the following are met
- Patient continues to meet initial authorization criteria.
- Prescribed dose does not exceed FDA-approved dosing based on patient age, weight, and diagnosis.
- Positive clinical response to NEMLUVIO (nemolizumab-ilto) therapy.
This policy applies only to FDA‑approved indications for NEMLUVIO (nemolizumab‑ilto). Use of NEMLUVIO for conditions or indications not described in the FDA labeling and not addressed in this document is outside the scope of this policy and is not covered by these prior authorization criteria. Prior authorization is required and will be considered only when the clinical criteria for the approved indication are met and supporting documentation is provided with the Universal PA Form.
Initial Therapy and Dosing
Re-authorization / Continuation Therapy
Re-authorization / Continuation Therapy
Re-authorization requires ongoing benefit
Continuation
- Patient continues to meet initial authorization criteria.
- Prescribed dose does not exceed FDA-approved dosing based on patient age, weight, and diagnosis.
- Positive clinical response to NEMLUVIO (nemolizumab-ilto) therapy as documented by the prescriber.
Step Therapy Requirements
| Step | Requirement | Provider action / documentation | Denial trigger |
|---|---|---|---|
| 1 | |||
| Prior trial of DUPIXENT (dupilumab) with inadequate response for at least 2 months | |||
| Document prior biologic therapy including start/stop dates, dose, and clinical assessment of response; include this information on the Universal PA form and supporting clinical notes | |||
| Missing documentation of at least a 2-month trial of dupilumab or lack of documentation of inadequate response |
Step therapy: prior trial of DUPIXENT required
Prior to approval for prurigo nodularis, the patient must have had an inadequate response after at least a 2‑month trial of DUPIXENT (dupilumab).
- Required trial duration: ≥ 2 months
- Documented inadequate response to DUPIXENT
Clinical Thresholds and Coding Values
Provider Requirements and Documentation
Prior authorization is required for NEMLUVIO
Prior authorization approval will be considered only when the listed clinical criteria are met. Submit the Universal PA Form and supporting clinical documentation with the request.
Required documentation to support PA
Include the Universal PA Form and supporting clinical documentation demonstrating PN diagnosis ≥3 months, WINRS score within the past month, total PN lesion count, prior dupilumab trial, prescriber specialty or consultation, and dosing consistent with FDA labeling.
- Universal PA Form (required)
- Documentation of prurigo nodularis duration ≥3 months
- WINRS (Worst Itch Numeric Rating Scale) score reported within the past month
- Total PN lesion count (≥20 lesions across both legs and/or both arms and/or trunk)
- Record of prior trial and inadequate response to DUPIXENT (dupilumab)
- Prescriber specialty or consultation (dermatologist, allergist/immunologist, or PN specialist)
- Prescribed dose consistent with FDA-approved dosing by age/weight/diagnosis
Common denial triggers
Requests may be denied if required criteria or documentation are missing — common triggers include no documented dupilumab trial or inadequate response, insufficient lesion count, or WINRS below the policy threshold.
- No documentation of at least a 2-month trial of DUPIXENT (dupilumab) with inadequate response
- WINRS score <7 or not reported within the past month
- Fewer than 20 total PN lesions documented
- Missing evidence of PN diagnosis duration ≥3 months
- Prescribed dose exceeds FDA-approved dosing or missing prescriber specialty/consult
Definitions and Clinical Measures
Background
Nemolizumab‑ilto is an interleukin‑31 receptor antagonist indicated for the treatment of adults with prurigo nodularis and for adults and pediatric patients ≥12 years with moderate‑to‑severe atopic dermatitis (when used with topical therapy as described in the label). For prurigo nodularis, the PA criteria in this policy require documentation of a PN diagnosis ≥3 months, WINRS ≥7 within the past month, a total of ≥20 PN lesions on specified body areas, a prior inadequate response to DUPIXENT (dupilumab) after at least a 2‑month trial, prescriber specialty or consultation, and dosing consistent with FDA‑recommended regimens. Dosing checks reference FDA labeling where adults <90 kg receive an initial 60 mg (two 30 mg injections) then 30 mg every 4 weeks, and adults ≥90 kg may receive 60 mg every 4 weeks.
OpenPayer is powered by Trek Health's payer performance platform. Trek continuously ingests, validates, and normalizes Transparency in Coverage data alongside payer policies and other commercial payer data to create a structured payer intelligence foundation. OpenPayer uses this foundation to deliver personalized search results, dynamically generated policy pages, and tailored policy monitoring based on each user's payers, specialties, billing codes, and areas of interest. The same intelligence powers broader payer performance workflows, including reimbursement benchmarking, contract evaluation, payer negotiations, and financial decision-making.